AbbVie Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? AbbVie Inc trades at $250.35 (market cap $438.19B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.6. The key difference: AbbVie Inc pays a 2.79% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none, and AbbVie Inc is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| ABBV | USOI | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $61.17 |
52-Week Low | $197.38 | $42.27 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
USOI (Credit Suisse X-Links Crude Oil Shares Covered Call ETN) trades at $45.05, up 0.2% with a bearish technical signal from moving averages. The ETN provides exposure to oil-linked covered call strategies, generating high yields but with complex risk exposure. Recent coverage highlights its unique structure and high yield potential amid shifting market dynamics.
The outlook remains cautious given the bearish technical setup and complex ETN structure. While the high yield strategy offers income potential, investors face significant commodity price volatility and counterparty risk. The lack of traditional equity fundamentals requires careful risk assessment of the underlying oil exposure and issuer creditworthiness.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →